Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 6/20 | 0.41 |
| ▸ | PPARA | Q07869 | 4/20 | 0.41 |
| ▸ | PPARD | Q03181 | 4/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 4/20 | 0.33 |
| ▸ | ACLY | P53396 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6730522 | 0.93 | PPARG (0.39) | PPARGPPARAPPARDOPRK1ALDH1A1 | |
| SCHEMBL6791341 | 0.89 | PPARG (0.41) | PPARGPPARAPPARDOPRK1ALDH1A1 | |
| SCHEMBL6733146 | 0.86 | PPARG (0.45) | PPARGPPARAPPARDOPRK1ALDH1A1 | |
| SCHEMBL6731589 | 0.85 | PPARG (0.41) | PPARGPPARAPPARDOPRK1ALDH1A1 | |
| SCHEMBL6728741 | 0.85 | PPARG (0.41) | PPARGPPARAPPARDALDH1A1KDM4E | |
| SCHEMBL6725421 | 0.83 | PPARG (0.43) | PPARGPPARAPPARDOPRK1ALDH1A1 | |
| SCHEMBL6737263 | 0.82 | PPARG (0.39) | PPARGPPARAPPARDALDH1A1KDM4E | |
| SCHEMBL6725126 | 0.81 | PPARG (0.41) | PPARGPPARAPPARDOPRK1ALDH1A1 | |
| SCHEMBL6733597 | 0.81 | PPARG (0.38) | PPARGPPARAPPARDOPRK1ALDH1A1 | |
| SCHEMBL6732137 | 0.81 | PPARG (0.44) | PPARGPPARAPPARDALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6747023-B1 | INHIBITORS FOR ACTIVATED COAGULATION FACTOR X, COAGULATION SUPPRESSORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-08 | — | — | US | disclosed |
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1104754-A1 | NOVEL SULFONYL DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-06-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | F2, CYC1, SULT2A1 | PPARG 1204/4885PPARA 573/4885PPARD 875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.